4results about How to "Reduce proliferation" patented technology

The invention discloses an application of samidocardone in preparation of a medicine for treating pulmonary fibrosis. According to the application disclosed by the invention, the condition that the samidojun can inhibit the activity of the pulmonary fibrosis cells and reduce proliferation by inducing the ferroptosis of the pulmonary fibrosis cells is proposed and verified for the first time, and meanwhile, the expression of fibrosis-related proteins is reduced, so that the progress of the pulmonary fibrosis is effectively relieved, and a new direction is provided for treating the pulmonary fibrosis.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-19b-3p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-19b-3p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-19b-3p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-19b-3p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

This invention relates to the field of biomedical technology, specifically to a micromolecule RNA-191-5p and its application in the treatment of pancreatic ductal adenocarcinoma. The micromolecule RNA-191-5p has the nucleotide sequence shown in SEQ ID NO:1. This invention discloses its use in the preparation of a medicament for treating pancreatic ductal adenocarcinoma, achieved by inhibiting the expression and / or activity of the micromolecule RNA-191-5p. The medicament comprises a substance capable of reducing the expression or activity of the micromolecule RNA-191-5p. This substance is its inhibitor, suppressor, antagonist, or antisense oligonucleotide. The medicament is used to inhibit the proliferation, migration, and / or invasion of pancreatic ductal adenocarcinoma cells. This invention provides a novel biomarker and therapeutic intervention target for pancreatic ductal adenocarcinoma, clarifies the feasibility of targeted therapy, and possesses clear translational potential.

The invention discloses a biomedical application of evobitacine A and a preparation method of the evobitacine A. The invention firstly proposes and verifies that the trident picrin A can inhibit the physiological activity of cells, particularly inhibit the activity of fibroblasts and reduce proliferation and migration, and also inhibits the expression of fibrosis-related proteins such as alpha-smooth muscle actin and / or type I collagen, thereby effectively inhibiting the progress of pulmonary fibrosis and improving the therapeutic effect of pulmonary fibrosis. The traditional Chinese medicine composition is a natural medicine with great application prospects.